U.S. drugmaker Bristol-Myers Squibb Co reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.
Bristol-Myers posts better-than-expected results, Opdivo growth slows
